20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.

20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.

Myofascial Pain Syndromes

Myofascial Trigger Point Pain

Trigger Point Pain, Myofascial

comparison of OnabotulinumtoxinA with placebo

OnabotulinumtoxinA

comparison of placebo with investigational drug OnabotulinumtoxinA

Placebo

University Case Medical Center

University Hospitals Landerbrook Health Center, Urology

University Hospitals Westlake Health Center, Urology

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Pelvic Floor Trigger Point Injection With OnabotulinumtoxinA for the Treatment of Severe Myofascial Pelvic Pain (MPP) - A Randomized, Controlled Trial

a 30% reduction of pain and muscular spasm assessed by visual analog scale - VAS

Reduction of pain and muscular spasm assessed at the 1 month visit by visual analog scale - VAS

assessed by validated patient-filled questionnaires

Assessed by clinical complications of therapy (including urinary retention by PVR and other associated complaints)

assessed by pelvic pain scores and pelvic floor pressures

assessed by pelvic pain scores after injection and/or by a change in treatment

assessed by urinary retention defined (PVR >150ml) and other associated complaints

Sangetta Mahajan MD

Assistant Professor & Head Division of Female Pelvic Medicine/Reconstructive Surgery/Obstetrics/Gynecology/Urology and Director of joint fellowship in Female Pelvic Medicine andReconstructive Surgery in the Departments of Obstetrics/Gynecology/Urology

pelvic inflammatory disease/головная боль

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Самая полная база данных о лекарственных травах, подтвержденная наукой